Literature DB >> 28893843

Timing of Angiography and Outcomes in High-Risk Patients With Non-ST-Segment-Elevation Myocardial Infarction Managed Invasively: Insights From the TAO Trial (Treatment of Acute Coronary Syndrome With Otamixaban).

Pierre Deharo1,2, Gregory Ducrocq3,4,5, Christoph Bode6, Marc Cohen7, Thomas Cuisset1, Shamir R Mehta8, Charles Pollack9, Stephen D Wiviott10, Yedid Elbez3,4,5, Marc S Sabatine10, Philippe Gabriel Steg11,4,5,12,13.   

Abstract

BACKGROUND: In patients with non-ST-segment-elevation myocardial infarction (NSTEMI) and GRACE (Global Registry of Acute Coronary Events) score >140, coronary angiography (CAG) is recommended by European and American guidelines within 24 hours. We sought to study the association of very early (ie, ≤12 hours), early (12-24 hours), and delayed (>24 hours) CAG in patients with NSTEMI with GRACE score >140 with ischemic outcomes.
METHODS: The TAO trial (Treatment of Acute Coronary Syndrome With Otamixaban) randomized patients with NSTEMI and CAG scheduled within 72 hours to heparin plus eptifibatide versus otamixaban. In this post hoc analysis, patients with a GRACE score >140 were categorized into 3 groups according to timing of CAG from admission (<12, ≥12-<24, and ≥24 hours). The primary ischemic outcome was the composite of all-cause death and myocardial infarction within 180 days of randomization.
RESULTS: CAG was performed in 4071 patients (<12 hours, n=1648 [40.5%]; 12-24 hours, n=1420 [34.9%]; ≥24 hours, n=1003 [24.6%]). With CAG ≥24 hours as a reference, CAG from 12 to 24 hours was not associated with a lower risk of primary ischemic outcome at 180 days (odds ratio, 0.96; 95% confidence interval, 0.75-1.23), whereas CAG <12 hours was associated with a lower risk of death and myocardial infarction (odds ratio, 0.71; 95% confidence interval, 0.55-0.91). Performing CAG <12 hours was also associated with a lower risk of death and myocardial infarction (odds ratio, 0.76; 95% confidence interval, 0.61-0.94; P=0.01) compared with CAG performed at 12 to 24 hours. No difference was observed in bleeding complications.
CONCLUSIONS: In patients with high-risk NSTEMI, undergoing CAG within the initial 12 hours after admission (as opposed to later, either 12-24 or ≥24 hours) was associated with lower risk of ischemic outcomes at 180 days.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  acute coronary syndrome; non-ST elevated myocardial infarction; percutaneous coronary intervention

Mesh:

Substances:

Year:  2017        PMID: 28893843     DOI: 10.1161/CIRCULATIONAHA.117.029779

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  11 in total

1.  Sex differences in quality indicator attainment for myocardial infarction: a nationwide cohort study.

Authors:  Chris Wilkinson; Owen Bebb; Tatendashe B Dondo; Theresa Munyombwe; Barbara Casadei; Sarah Clarke; François Schiele; Adam Timmis; Marlous Hall; Chris P Gale
Journal:  Heart       Date:  2018-11-23       Impact factor: 5.994

2.  Simple risk score based on the China Acute Myocardial Infarction registry for predicting in-hospital mortality among patients with non-ST-segment elevation myocardial infarction: results of a prospective observational cohort study.

Authors:  Chenxi Song; Rui Fu; Sidong Li; Jingang Yang; Yan Wang; Haiyan Xu; Xiaojin Gao; Jia Liu; Qianqian Liu; Chunyue Wang; Kefei Dou; Yuejin Yang
Journal:  BMJ Open       Date:  2019-09-12       Impact factor: 2.692

Review 3.  Drug-eluting balloon: is it useful?

Authors:  Sidhi Laksono; Budhi Setianto; Steven Philip Surya
Journal:  Egypt Heart J       Date:  2020-11-11

4.  Which Out-of-Hospital Cardiac Arrest Patients without ST-Segment Elevation Benefit from Early Coronary Angiography? Results from the Korean Hypothermia Network Prospective Registry.

Authors:  Hwan Song; Hyo Joon Kim; Kyu Nam Park; Soo Hyun Kim; Won Young Kim; Byung Kook Lee; In Soo Cho; Jae Hoon Lee; Chun Song Youn
Journal:  J Clin Med       Date:  2021-01-23       Impact factor: 4.241

5.  Pre hospital delay and its associated factors in acute myocardial infarction in a developing country.

Authors:  Ishmum Zia Chowdhury; Md Nurul Amin; Mashhud Zia Chowdhury; Sharar Muhib Rahman; Mohsin Ahmed; F Aaysha Cader
Journal:  PLoS One       Date:  2021-11-24       Impact factor: 3.240

6.  The Relevance of Interventional Time and Clinical Outcomes in Patients with NSTEMI Based on the GRACE Score.

Authors:  Ji-Xiang Wang; Jing Gao; Jian-Yong Xiao; Ming-Dong Gao; Nan Zhang; Peng-Ju Lu; Yin Liu
Journal:  Appl Bionics Biomech       Date:  2022-04-29       Impact factor: 1.664

7.  Prognostic benefit from an early invasive strategy in patients with non-ST elevation acute coronary syndrome (NSTEACS): evaluation of the new risk stratification in the NSTEACS European guidelines.

Authors:  Jesús Martinón-Martínez; Belén Álvarez Álvarez; Teba González Ferrero; Federico García-Rodeja Arias; Óscar Otero García; Carla Cacho Antonio; Charigan Abou Jokh Casas; Pilar Zuazola; Alberto Cordero; David Escribano; Belén Cid Alvarez; Diego Iglesias Álvarez; Rosa Agra Bermejo; Pedro Rigueiro Veloso; José María García Acuña; Francisco Gude Sampedro; José Ramón González Juanatey
Journal:  Clin Res Cardiol       Date:  2021-03-09       Impact factor: 5.460

8.  An Approach to Accelerate Healing and Shorten the Hospital Stay of Patients With Anastomotic Leakage After Esophagectomy: An Explorative Study of Systematic Endoscopic Intervention.

Authors:  LeQi Zhong; JiuDi Zhong; ZiHui Tan; YiTong Wei; XiaoDong Su; ZheSheng Wen; TieHua Rong; Yi Hu; KongJia Luo
Journal:  Front Oncol       Date:  2021-05-17       Impact factor: 6.244

9.  Early invasive strategy for non-ST elevation acute coronary syndrome: a meta-analysis of randomized, controlled trials.

Authors:  Ying Li; Cuancuan Wang; Yue Nan; Hui Zhao; Zhongnan Cao; Xinping Du; Kuan Wang
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

10.  Oral Antiplatelet Therapy Administered Upstream to Patients With NSTEMI.

Authors:  Charles V Pollack; W Frank Peacock; Durgesh D Bhandary; Steven H Silber; Narinder Bhalla; Sunil V Rao; Deborah B Diercks; Alex Frost; Sripal Bangalore; John F Heitner; Charles Johnson; Renato DeRita; Naeem D Khan
Journal:  Crit Pathw Cardiol       Date:  2020-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.